44322 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Santa Cruz Biotechnology plk1 targeting sirna
    A. Polo-like kinase 1 <t>(PLK1)</t> expression was examined via immunoblotting, with actin as the loading control. B. , E. K562 or Ba/F3 T315I cells were treated with the indicated concentrations of rigosertib for 72 h. The percentages of cell growth were examined; * P < 0.05 compared with the control. Results represent three separate experiments. C. K562 cells were treated with the indicated concentrations of rigosertib for 48 h. Percentages of apoptotic cells were examined. These results represent three independent experiments; * P < 0.05 compared with the control. D. , F. K562 or Ba/F3 T315I cells were treated with rigosertib at the indicated concentrations for 24 h. Total extracts were examined via immunoblotting with anti-phospho ABL, phospho-Crk-L, phosphohistone H2A.X, cleaved caspase 3, cleaved-PARP, ABL, Crk-L, and β-actin antibodies (abs). ABL, Abelson; PARP, poly (ADP-ribose) polymerase; abs, antibodies.
    Plk1 Targeting Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plk1 targeting sirna/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    plk1 targeting sirna - by Bioz Stars, 2024-04
    93/100 stars
      Buy from Supplier

    86
    SAS institute rue de la géraudière cs 82225 f 44322 nantes cedex 3 6stevia natura sas
    A. Polo-like kinase 1 <t>(PLK1)</t> expression was examined via immunoblotting, with actin as the loading control. B. , E. K562 or Ba/F3 T315I cells were treated with the indicated concentrations of rigosertib for 72 h. The percentages of cell growth were examined; * P < 0.05 compared with the control. Results represent three separate experiments. C. K562 cells were treated with the indicated concentrations of rigosertib for 48 h. Percentages of apoptotic cells were examined. These results represent three independent experiments; * P < 0.05 compared with the control. D. , F. K562 or Ba/F3 T315I cells were treated with rigosertib at the indicated concentrations for 24 h. Total extracts were examined via immunoblotting with anti-phospho ABL, phospho-Crk-L, phosphohistone H2A.X, cleaved caspase 3, cleaved-PARP, ABL, Crk-L, and β-actin antibodies (abs). ABL, Abelson; PARP, poly (ADP-ribose) polymerase; abs, antibodies.
    Rue De La Géraudière Cs 82225 F 44322 Nantes Cedex 3 6stevia Natura Sas, supplied by SAS institute, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rue de la géraudière cs 82225 f 44322 nantes cedex 3 6stevia natura sas/product/SAS institute
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rue de la géraudière cs 82225 f 44322 nantes cedex 3 6stevia natura sas - by Bioz Stars, 2024-04
    86/100 stars
      Buy from Supplier

    N/A
    Standard format Plasmid sent in bacteria as agar stab
      Buy from Supplier

    Image Search Results


    A. Polo-like kinase 1 (PLK1) expression was examined via immunoblotting, with actin as the loading control. B. , E. K562 or Ba/F3 T315I cells were treated with the indicated concentrations of rigosertib for 72 h. The percentages of cell growth were examined; * P < 0.05 compared with the control. Results represent three separate experiments. C. K562 cells were treated with the indicated concentrations of rigosertib for 48 h. Percentages of apoptotic cells were examined. These results represent three independent experiments; * P < 0.05 compared with the control. D. , F. K562 or Ba/F3 T315I cells were treated with rigosertib at the indicated concentrations for 24 h. Total extracts were examined via immunoblotting with anti-phospho ABL, phospho-Crk-L, phosphohistone H2A.X, cleaved caspase 3, cleaved-PARP, ABL, Crk-L, and β-actin antibodies (abs). ABL, Abelson; PARP, poly (ADP-ribose) polymerase; abs, antibodies.

    Journal: Oncotarget

    Article Title: Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells

    doi:

    Figure Lengend Snippet: A. Polo-like kinase 1 (PLK1) expression was examined via immunoblotting, with actin as the loading control. B. , E. K562 or Ba/F3 T315I cells were treated with the indicated concentrations of rigosertib for 72 h. The percentages of cell growth were examined; * P < 0.05 compared with the control. Results represent three separate experiments. C. K562 cells were treated with the indicated concentrations of rigosertib for 48 h. Percentages of apoptotic cells were examined. These results represent three independent experiments; * P < 0.05 compared with the control. D. , F. K562 or Ba/F3 T315I cells were treated with rigosertib at the indicated concentrations for 24 h. Total extracts were examined via immunoblotting with anti-phospho ABL, phospho-Crk-L, phosphohistone H2A.X, cleaved caspase 3, cleaved-PARP, ABL, Crk-L, and β-actin antibodies (abs). ABL, Abelson; PARP, poly (ADP-ribose) polymerase; abs, antibodies.

    Article Snippet: PLK1-targeting siRNA was purchased from Santa Cruz Biotechnology (sc-36277).

    Techniques: Expressing, Western Blot

    A. PLK1 protein expression was measured via immunoblotting with a PLK1-specific antibody. β-actin was used as a loading control. B. PLK1 and control siRNA transfected cells were incubated with imatinib for 72 h. Viable cell numbers were counted; * P < 0.05 compared with control siRNA transfected cells. These results represent three separate experiments. C. Cells were treated with imatinib for 48 h. Percentages of apoptotic cells were determined; P < 0.05 compared with control siRNA transfected cells. Results represent three independent experiments. D. Cells were treated with imatinib for 24 h. Whole extracts were examined via immunoblotting with anti-phospho ABL, phospho-Crk-L, cleaved-PARP, and β-actin antibodies. ABL, Abelson; PARP, poly (ADP-ribose) polymerase.

    Journal: Oncotarget

    Article Title: Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells

    doi:

    Figure Lengend Snippet: A. PLK1 protein expression was measured via immunoblotting with a PLK1-specific antibody. β-actin was used as a loading control. B. PLK1 and control siRNA transfected cells were incubated with imatinib for 72 h. Viable cell numbers were counted; * P < 0.05 compared with control siRNA transfected cells. These results represent three separate experiments. C. Cells were treated with imatinib for 48 h. Percentages of apoptotic cells were determined; P < 0.05 compared with control siRNA transfected cells. Results represent three independent experiments. D. Cells were treated with imatinib for 24 h. Whole extracts were examined via immunoblotting with anti-phospho ABL, phospho-Crk-L, cleaved-PARP, and β-actin antibodies. ABL, Abelson; PARP, poly (ADP-ribose) polymerase.

    Article Snippet: PLK1-targeting siRNA was purchased from Santa Cruz Biotechnology (sc-36277).

    Techniques: Expressing, Western Blot, Transfection, Incubation